CAR-T Cell Therapy Targeting to CD19 for R/R ALL

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

August 30, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Lymphoblastic Leukemia with Failed Remission
Interventions
BIOLOGICAL

CAR T-cell therapy

Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).

Trial Locations (1)

215006

The Fisrt Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

Third Military Medical University

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT03919240 - CAR-T Cell Therapy Targeting to CD19 for R/R ALL | Biotech Hunter | Biotech Hunter